Seòmar agus comataidhean

A breakdown of these awards by local authority area is not currently gathered although this information is collected at application entry level and is as follows:

The Scottish Government is aware of the vast challenges in attempting to ensure pancreatic enzyme replacement therapy is offered to every patient at the point of diagnosis.

Pancreatic cancer patients can present as asymptomatic despite pancreatic exocrine insufficiency, while patients can also be diagnosed through many different pathways.

This can result in clinicians not always having the specialist knowledge and experience to know about the importance of pancreatic enzyme replacement therapy.

The Scottish Governments National Cancer Recovery Plan will help address this knowledge gap by working to review Cancer Clinical Management Guidelines in liaison with relevant parties.

Under the National Cancer Recovery Plan, we have funded the Scottish HepatoPancreatoBiliary Cancer Network (SHPBN) which is reviewing guidelines to address this issue.

I refer the member to the answer to question S5W-00633 on 13 July 2021. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

The information requested is not held centrally by the Scottish Government.

The data is collected by individual NHS Health Boards and would require permissions from each to be obtained in order to conduct appropriate data linkage analysis by Public Health Scotland.

There are some circumstances where there are legitimate reasons for not prescribing pancreatic enzyme replacement therapy, such as palliative patients or due to patient’s cultural preference. However, we understand more can be done around education and monitoring to ensure our clinicians are aware of the treatment.

As part of The Scottish Governments National Cancer Recovery Plan , published in December 2020, funding has been made available to ensure equitable access to treatments across the whole of Scotland.

This includes our funded work being led by The Scottish HepatoPancreatoBiliary Network which will be directly addressing guidance on the use of pancreatic enzyme replacement therapy.

I refer the member to the answer to question S5W-00633 on‎ 13 July 2021. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

The Scottish Government stepped in to take ownership, to ensure a viable future for the yard, its workforce and completion of the much needed vessels. The Scottish Government continues to work closely with the yard to explore all possible options to ensure a viable future for the business.

MV Glen Sannox was launched in November 2017. For Hull 802, much of the outfitting will be carried out before launch, making the work more efficient. As a result 802 will weigh over 1,000 tonnes more than Glen Sannox, meaning the tide conditions will be critical. Detailed engineering analysis is required to balance the tide, launch arrangement and weight to find the most effective combination.

The Scottish Government are in contact with Ferguson Marine on a regular basis. The Ferguson Marine Board of Directors visited the yard on 3 June to discuss the Turnaround Directors update to the Scottish Parliament. The Board subsequently signed off the revised schedule in early June and this information was then shared with the Scottish Government.

Full details of Scottish Government budget allocations, including those to Local Government can found in the Scottish Government annually published Scottish Budget at Publications - gov.scot (www.gov.scot).